Few data are available so far on the role of CD20+ T cells as potential biomarkers of disease activity in MS, highlighting potential associations between this cell population and relapses, MRI activity, and serum/CSF markers of demyelination and axonal damage. Here, MS4A1 is linked to myeloid sarcoma.